BAFNAPH
Bafna Pharmaceuticals Limited (BAFNAPH) Stock Analysis
Bafna Pharmaceuticals Limited is an Indian pharmaceutical company manufacturing formulations across therapeutic areas. It markets generic medicines in domestic and export markets from Tamil Nadu facilities. The company operates in the small and mid-size pharma segment. It is a listed pharma stock.
Healthcare › Drug Manufacturers - Specialty & Generic
₹418.00
+10.36% 1W | +152.40% 52W
Market Cap
989 CR
P/E Ratio
127.1
52W High
₹418
52W Low
₹94.8
Div. Yield
0%
Beta
0.1
50 DMA
₹299.4
200 DMA
₹183.3
Profit Margin
5.5%
Inst. Own.
0%
🚀 BREAKOUT
🚀 BREAKOUT
Fundamentals
Profit & Loss
| Metric | Jun 2018 | Sep 2018 | Jun 2019 | Sep 2019 |
|---|---|---|---|---|
| Sales | 11.95 | 8.84 | 6.85 | 11.57 |
| Expenses | 13.77 | 8.66 | 9.71 | 11.95 |
| Operating Profit | -1.82 | 0.18 | -2.86 | -0.38 |
| OPM % | -15.23% | 2.04% | -41.75% | -3.28% |
| Other Income | 0.09 | -0.03 | 0.30 | 0.59 |
| Interest | 0.83 | 0.62 | 0.13 | 0.04 |
| Depreciation | 1.00 | 0.75 | 1.02 | 0.72 |
| Profit before tax | -3.56 | -1.22 | -3.71 | -0.55 |
| Tax % | -1.12% | 4.10% | -42.59% | 7.27% |
| Net Profit | -3.52 | -1.28 | -2.13 | -0.59 |
| EPS in Rs | -1.49 | -0.54 | -0.90 | -2.49 |
| Metric | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 129 | 175 | 185 | 97 | 85 | 65 | 46 | 44 | 42 |
| Expenses | 110 | 153 | 162 | 114 | 85 | 71 | 81 | 57 | 41 |
| Operating Profit | 19 | 22 | 23 | -18 | 1 | -6 | -35 | -13 | 1 |
| OPM % | 15% | 13% | 12% | -18% | 0.6% | -9% | -77% | -30% | 2.9% |
| Other Income | 1 | 3 | 2 | 43 | 2 | 1 | 31 | 1 | -22 |
| Interest | 8 | 12 | 13 | 13 | 13 | 11 | 7 | 2 | 0 |
| Depreciation | 6 | 8 | 9 | 6 | 5 | 4 | 4 | 3 | 3 |
| Profit before tax | 5 | 5 | 2 | 6 | -15 | -20 | -15 | -17 | -24 |
| Tax % | 64% | 27% | 42% | -2% | -1% | -4% | 15% | 6% | 0% |
| Net Profit | 2 | 4 | 1 | 6 | -15 | -19 | -17 | -18 | -24 |
| EPS in Rs | 1.00 | 2.12 | 0.75 | 3.31 | -7.52 | -10.23 | -7.08 | -7.98 | -104.54 |
| Dividend Payout % | 0% | 28% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | -13.0% | -15.0% | – |
| Profit CAGR | 24.0% | 14.0% | – |
Shareholding Pattern
Promoters75.00%
FIIs9.34%
Public15.66%
Promoters75.00%
FIIs9.34%
Public15.66%
Promoters75.00%
FIIs9.34%
Public15.66%
Promoters75.00%
FIIs9.34%
Public15.66%
Promoters75.00%
FIIs9.34%
Public15.66%
Promoters89.99%
Public10.00%
Promoters88.29%
Public11.70%
Promoters75.00%
FIIs8.53%
Public16.47%
Promoters75.00%
FIIs9.34%
Public15.66%
Promoters75.00%
FIIs9.34%
Public15.66%
BAFNAPH
Holdings Analysis
Key strengths & risk signals
66
Overall
55
Fundamental
77
Technical
Risks (3)
Cannot calculate PEG - insufficient growth data.
BEARISH SENTIMENT! In last 30 days: 24 up days, 6 down days. Avg volume on up days: 6,469 vs down days: 9,257. Ratio: 0.7x
OVERBOUGHT! RSI at 90.3 - caution, may pull back.
Strengths (4)
GOOD STABILITY! Only 1 revenue dip in history. Strong business fundamentals.
BULLISH TREND! 50-day average (299.4) is above 200-day average (183.3) - positive signal.
BREAKOUT! Stock has broken above resistance levels with momentum.
EXCELLENT YEAR! Stock gained 152.4% in the last year.
Fundamental & Technical Analysis
66Overall
55Fundamental
77Technical
Fundamental Breakdown
Growth Quality
10/30
Revenue CAGR: 9.3% (MODERATE, 8/15). Profit CAGR: -0.7% (DECLINING, 2/15).
Profit Margin
3/10
LOW MARGIN! 5.5% profit margin - thin profits.
PEG Valuation
1/10
Cannot calculate PEG - insufficient growth data.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
20/20
VERY LESS PUBLIC HOLDING! 10.0% public ownership - strong promoter/institutional control.
Stability Index
8/10
GOOD STABILITY! Only 1 revenue dip in history. Strong business fundamentals.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (299.4) is above 200-day average (183.3) - positive signal.
Price Position
8/10
STRONG POSITION! Current price (418.0) is above both moving averages.
Trend Pattern
20/20
BREAKOUT! Stock has broken above resistance levels with momentum.
52W Performance
10/10
EXCELLENT YEAR! Stock gained 152.4% in the last year.
Volume Sentiment
10/30
BEARISH SENTIMENT! In last 30 days: 24 up days, 6 down days. Avg volume on up days: 6,469 vs down days: 9,257. Ratio: 0.7x
RSI
2/5
OVERBOUGHT! RSI at 90.3 - caution, may pull back.
52W Range
5/5
STRONG! Trading at 100.0% of 52W range - near yearly highs.
Momentum
5/5
STRONG MOMENTUM! Price has grown across all timeframes - up 10.4% (1 week), 38.6% (1 month), 104.3% (3 months). Momentum is accelerating.
Beta
5/5
LOW VOLATILITY! Beta of 0.10 - stable stock, less market risk.
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BAFNAPH | ₹418.00 | 127.1 | 5.5% | 9.3% | -0.7% | +152.4% | 66 | BREAKOUT | -97.1% | -96.3% | -23.1% | -37.0% |
| THEMISMED | ₹108.60 | 25.1 | 12.1% | -0.4% | -72.8% | -16.1% | 53 | BREAKDOWN | -273.2% | +176.4% | -10.9% | +13.7% |
| LINCOLN | ₹558.30 | 11.6 | 13.9% | 9.5% | 6.4% | +6.6% | 57 | BREAKDOWN | +30.7% | +212.1% | +15.1% | -5.3% |
| SIGACHI | ₹28.50 | 42.6 | 5.4% | 16.5% | – | -24.4% | 56 | BREAKDOWN | -106.8% | -11.7% | -5.4% | -0.5% |
| BAJAJHCARE | ₹320.00 | 46.2 | 2.8% | -1.8% | -28.4% | -32.8% | 44 | BOUNCE FROM SUPPORT | +16.1% | -159.8% | +11.3% | +8.2% |
| KILITCH | ₹241.60 | 27.4 | 12.7% | 19.2% | 42.4% | +41.9% | 84 | BREAKOUT | -3.3% | -80.0% | +4.2% | -49.9% |
| ANUHPHR | ₹82.00 | 18.6 | 5.7% | 13.5% | 4.3% | +4.0% | 64 | BREAKDOWN | +37.3% | -2.6% | +3.9% | -4.1% |
| ZIMLAB | ₹150.50 | 183.5 | 0.9% | -2.5% | -37.9% | +105.9% | 57 | APPROACHING RESISTANCE | +110.5% | -208.1% | +31.2% | -10.5% |
Data from TradeAlone · Updated daily
No news tagged for BAFNAPH yet.
